D-Boramine Therapeutic Agent Formulation for Genetic Mutation Correction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic agents for preventing and treating cancers and infections related to BRCA1 and BRCA2 gene mutations, viral infections, and other diseases are often ineffective, complex to synthesize, and fail to address genetic and epigenetic mutations at the cellular level, particularly in correcting somatic and germ-line defects.
Innovation Solution
A therapeutic agent, D-Boramine, is formulated by combining L-carnitine tartrate, pyridoxal-5′-phosphate, and fumaric acid in specific weight proportions, allowing for the correction of genetic and epigenetic mutations in both somatic and germ-line cells, and is administered orally or parenterally to treat various diseases including cancers and viral infections.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapeutic agents are used to treat cancers and infections, then treatment is attempted, but effectiveness is poor and synthesis methods are complex
Solution Approach 1:
The patent combines multiple ingredients (L-carnitine tartrate, pyridoxal-5'-phosphate, fumaric acid) into a single formulated therapeutic agent D-Boramine, simplifying the synthesis process while improving effectiveness. This merging of components resolves the contradiction by creating a unified formulation that is easier to manufacture than complex multi-step synthesis methods while achieving better therapeutic outcomes.
Solution Approach 2:
The patent specifies particular weight proportions for the ingredients in D-Boramine (L-carnitine tartrate: 34-90%, pyridoxal-5'-phosphate: 5-33%, fumaric acid: 0.5-33%), optimizing the formulation parameters to enhance effectiveness. By carefully controlling these parameters, the patent achieves improved therapeutic reliability without requiring complex synthesis procedures.
2Reliability
If conventional therapeutic agents are used, then treatment is provided, but they fail to correct genetic and epigenetic mutations at the cellular level
Solution Approach 1:
The patent employs D-Boramine as an intermediary substance that acts at the cellular level to correct genetic and epigenetic mutations. This intermediary formulation enables the correction of BRCA1, BRCA2, and MTHFR gene mutations, as well as restoring proper protein morphology and folding, thereby improving effectiveness without requiring overly complex mechanisms.
Solution Approach 2:
The patent replaces conventional mechanical or chemical treatment approaches with a biochemical mechanism that operates at the cellular and molecular levels. By using D-Boramine to restore epigenetic signaling and correct gene mutations, the patent achieves more precise and effective treatment without relying on complex mechanical systems or procedures.
3Reliability
If existing vaccines and antiviral agents are used, then infection treatment is attempted, but success is limited and virus destruction is not achieved
Solution Approach 1:
The patent employs D-Boramine to enable the body's own cellular mechanisms to fight infections and destroy viruses. By restoring proper cellular function and epigenetic signaling, the formulation allows the body to mount effective defenses against viral infections, achieving virus destruction without requiring complex vaccine production processes.
Data Source
AI summary
The present invention relates to a therapeutic agent, wherein the therapeutic agent is D-Boramine. The therapeutic agent is prepared by mixing L-carnitine tartrate, pyridoxal 5′ phosphate and fumaric acid. D-Boramine, when administered orally or parenterally in therapeutic quantities, is effective for use in the prevention of cancer that arises from mutations to the BRCA1 and BRCA2 genes, i.e., breast and ovarian and the treatment of several types of human diseases including, but not limited to, Antiphospholipid Syndrome, Disseminate Intravascular Coagulation (DIC), infections arising from viruses (including strains of Human Papillomavirus, Herpes Simplex Virus and Simian Virus), tuberculosis (including XDR Tuberculosis) and mycoplasma, Hepatitis A, B and C, MTHFR genetic mutations.